**Combining seasonal malaria chemoprevention with novel therapeutics for malaria**
**prevention: a mathematical modelling study**

Lydia Braunack-Mayer[1, 2] PhD, Josephine Malinga[3,4] PhD, Narimane Nekkab[1, 2] PhD, Sherrie L Kelly[1] PhD, Jörg J
Möhrle[1, 2, 4] PD, Melissa A Penny[1, 2, 3, 5, *] Prof

1 Swiss Tropical and Public Health Institute, Allschwil, Switzerland
2 University of Basel, Basel, Switzerland
3 The Kids Research Institute Australia, Nedlands, WA, Australia
4 Medicines for Malaria Venture, Geneva, Switzerland
5 Centre for Child Health Research, The University of Western Australia, Crawley, WA, Australia
* Correspondence to:

Prof Melissa A Penny
**melissa.penny@uwa.edu.au**

**Abstract**

**Background:** Vaccines, monoclonal antibodies, and long-acting injectables are being developed to prevent
*Plasmodium falciparum* malaria. These therapeutics may target multiple stages of the parasite life cycle, and
evidence is needed to articulate their benefits with chemoprevention and prioritise candidates for clinical
development.

**Methods:** We used an individual-based malaria transmission model to estimate the health impact of combining new
therapeutics with seasonal malaria chemoprevention (SMC). Our modelling framework used emulator-based
methods with models of pre-liver and blood stage therapeutic dynamics. We evaluated the benefit of combining
therapeutics with SMC in children under five by estimating reductions in the cumulative incidence of uncomplicated
and severe malaria, relative to SMC or the new therapeutic alone, during and five years after deployment.

**Results:** New therapeutics may require extended pre-liver stage duration or multi-stage activity to combine with
SMC. For three SMC cycles in a high transmission setting, a pre-liver stage therapeutic with partial initial efficacy
(>50%) required a protection half-life >230 days to reduce cumulative severe cases by >5% five years after
deployment stopped (>23% during interventions). Longer protection was needed when combined with four or five
SMC cycles. Combining SMC with a multi-stage therapeutic increased public health impact both during and after
deployment.

**Conclusions:** Combining SMC with malaria therapeutics active against multiple stages of the parasite life cycle can
improve the effectiveness of SMC, highlighting the need to prioritise the clinical development of these therapeutics
for combination with malaria chemoprevention.

**Key words:** *Plasmodium falciparum*; malaria therapeutics; multi-stage; intervention combinations; modelling;
seasonal malaria chemoprevention

## Background

The first five years of a child's life play a pivotal role in shaping their long-term health and development, and early childhood illness can significantly impact a child's ability to learn and succeed later in life.[1] Nevertheless, in regions of the world where *Plasmodium falciparum* malaria is endemic, this crucial period in a child's life coincides with their highest vulnerability to malaria infection. The World Health Organization estimates that, in 2022, approximately 452 000 children under the age of five years died of malaria in Africa.[2] In Sub-Saharan regions of Africa, public health interventions, such as insecticide treated nets[3] and chemoprevention,[4] are crucial to provide children with tools that prevent malaria during these formative years.

In a number of African regions, the high-risk period for *Plasmodium falciparum* malaria transmission coincides with the rainy season. The World Health Organization recommends seasonal malaria chemoprevention (SMC), which clears existing infections and prevents new cases through monthly cycles of an antimalarial drug.[4] The drug combination sulfadoxine-pyrimethamine with amodiaquine (SP-AQ) has been widely used for SMC in children,[4] achieving a 88·2% (95% CI 78·7–93·4) mean reduction in the incidence of clinical malaria in children younger than five years when deployed at scale.[5] However, children do not always comply with the full treatment course of SP-AQ, high levels of coverage are not always achieved, and SMC's effectiveness may be compromised due to the spread of partial *Plasmodium falciparum* resistance to SP.[5,6] These gaps leave some children at risk of malaria infection during a crucial period in their development.

In 2021, the first randomised control trial was completed for SMC with SP-AQ in combination with malaria vaccination.[7] This study combined up to five cycles of an established chemoprevention intervention with seasonal deployment of the first approved malaria vaccine, RTS,S/AS01E (RTS,S). SP-AQ acts to clear blood stage parasites and prevent liver stages from emerging into the blood, while RTS,S is a pre-liver stage vaccine that prevents liver stage infection by targeting surface antigens of sporozoite parasites. The combination of a pre-liver stage vaccine with SMC was found to be superior to SMC alone.[7–9] SMC has also been studied in combination with the R21/Matrix-M malaria pre-liver stage vaccine.[10] And, modelling studies have identified the potential for substantial public health benefits from combining RTS,S with SMC.[11] These successes demonstrate that a pre-liver stage vaccine can be used to strengthen the effectiveness of malaria chemoprevention and to achieve significant reductions in childhood burden. However, it is not yet known whether alternative therapeutics will provide similar benefits, or whether therapeutics that target additional stages of the parasite life cycle could be more effective.

Recent developments in vaccines, monoclonal antibodies, and long-acting injectable drugs suggest opportunities to combine chemoprevention with therapeutics other than pre-liver stage vaccines, including with therapeutics active against multiple stages of the parasite life cycle. The first phase two clinical trial results for a pre-liver stage monoclonal antibody are now available.[12] This class of therapeutic can provide high levels of protection following a single dose, making it a likely candidate for seasonal deployment. But concerns remain regarding the cost-effectiveness of monoclonal antibodies when deployed at scale.[13,14] Injectable formulations of existing antimalarial drugs, such as atovaquone-proguanil, may offer children three to four months of protection at a lower cost than monoclonal antibodies.[14–17] These re-formulations can target multiple stages of the parasite life cycle by, for example, combining drug partners with both liver stage and blood stage activity. There are also candidates for multi-stage in development, including whole-sporozoite,[18] blood stage,[19] and transmission blocking vaccines.[20] Each of these novel therapeutics could be combined with SMC to improve the effectiveness of childhood malaria interventions. But each of these novel therapeutics has different profiles, encompassing differences in the levels of protection provided immediately following administration, the length of protection afforded, and their rate of efficacy decay. It is not yet known how these differences in therapeutic properties will relate to their public health impact once combined with SMC.

In this modelling study, we explored and defined the essential properties needed for a seasonally deployed, novel malaria therapeutic to increase the effectiveness of SMC throughout childhood. By novel therapeutic, we refer to a

malaria vaccine, monoclonal antibody, or long-acting injectable drug that has not yet been approved for use in
children. Our research combined an established, individual-based malaria transmission model with statistical
modelling techniques, quantifying the therapeutic properties required for a new therapeutic to contribute additional
reductions in cumulative uncomplicated and severe cases in children, in comparison to the standard of care. Our
results encompassed vaccines, monoclonal antibodies, and novel long-acting therapeutics with both activity against
a single-stage of the parasite life cycle (either pre-liver or blood stage) and activity against multiple stages (pre-liver
combined with blood stage, referred to as multi-stage therapeutics). Through this evidence, we have aimed to
provide funders, policymakers, and developers with guidance to inform candidate selection of malaria therapeutics
with adequate properties to meet public health goals in advance of phase two and three clinical trials.

**Methods**

**Malaria transmission model**

We used an established model of malaria transmission to predict the impact of combining SMC with seasonal
deployment of a novel therapeutic. This individual-based model, called OpenMalaria
(https://github.com/SwissTPH/openmalaria/wiki), has been fully described previously.[21] OpenMalaria combines
multiple, smaller models that each represent a component in the malaria transmission lifecycle. Model components
simulate the dynamics of mosquito populations, malaria parasitaemia in the course of an infection, onward
transmission, and the processes leading to clinical illness, severe disease, and death (appendix table 1.1). This model
has been validated to historical data on a range of epidemiological outcomes, including patterns of age-specific
prevalence and incidence, and age-specific rates for malaria mortality and hospitalisation.[21]

OpenMalaria's model components capture the dynamics of acquired immunity to the asexual blood stages of
*Plasmodium falciparum* infection. Acquired immunity is represented as a function of an individual's cumulative
density of asexual parasitaemia since birth, including maternal immunity, and their total number of prior infections.
Infection densities are drawn from parasitaemia records of malaria naive patients infected with *Plasmodium*
*falciparum* for treatment of neurosyphilis.[22–24] The number of prior infections influences pre-erythrocytic immunity,
and both prior infections and cumulative asexual parasitaemia influence blood stage immunity. Immunity acts by
reducing an infected host's parasite densities and affecting the probability that parasitaemia will reach the specific
parasite densities, or pyrogenic thresholds, that trigger symptoms of uncomplicated and severe malaria.[23,24]

**Intervention dynamics and deployment**

Using our individual-based model of malaria transmission, we simulated the deployment of SMC with SP-AQ
combined with a range of therapeutics for malaria prevention in children. To simulate SMC, we deployed monthly
cycles of SP-AQ to children aged between three and 59 months old. SP-AQ is modelled with both a preventative
and a curative action, simultaneously preventing the emergence of liver stage parasites and clearing both blood stage
and liver stage parasitaemia at the time of administration (table 1). Model parameter values were previously
calibrated to data from a randomised non-inferiority trial of SMC with SP-AQ.[25,26]

| Therapeutic | Modelled action | Modelled parameter range | | |
|---|---|---|---|---|
| | | **Initial efficacy (%)** Therapeutic effect at time of administration as % of maximum possible effect | **Protection half-life (days)** Number of days until effect decays to 50% of initial efficacy, scale parameter used in the Weibull function for effect decay | **Decay shape (numeric)** Shape parameter used in the Weibull function for effect decay |
| SP-AQ | Prevents a proportion of infections from commencing, clears blood stage infection, and clears liver | 100% | 31·1 | 5·34 |

| | stage infection | | | |
|---|---|---|---|---|
| Pre-liver stage profile | Prevents a proportion of infections from commencing | Sampled randomly between 30 and 100% | Sampled randomly between 30 and 500 days | Sampled randomly between 0 and 10 |
| Blood stage profile | Kills a proportion of blood stage parasites | Sampled randomly between 30 and 100% | Sampled randomly between 30 and 500 days | Sampled randomly between 0 and 10 |

**Table 1: Model assumptions for therapeutic dynamics**

SP-AQ was deployed as up to five yearly cycles of SMC, spaced four weeks apart and timed to cover the malaria transmission season. Model
parameter values were previously calibrated to data from a randomised non-inferiority trial of SMC with SP-AQ.[25,26] The novel therapeutic was
deployed at the same time as the first cycle of SMC and consisted of the following combinations of model components: pre-liver stage activity
alone, blood stage activity alone, and the combination of pre-liver stage and blood stage activity. A range of possible novel profiles were explored
by generating 500 Latin hypercube samples of parameter values for component initial efficacy, protection half-life, and decay shape. Efficacy
decay was calculated with a Weibull function of time t following administration $E \times \exp(-(\frac{t}{L})^k \times \log(2))$, where E was the component's initial
efficacy at the time of administration, L was the protection half-life or number of days until therapeutic efficacy reached half of its initial
efficacy, and k influenced the rate of efficacy decay.

We represented the activity of a range of malaria vaccine, monoclonal antibody, and long-acting injectable drug
candidates with both single- and multi-stage activity by combining explicit models of pre-liver stage and blood stage
profiles, as shown in table 1. Key model parameters included the profile's initial efficacy at the time of
administration, the protection half-life or number of days until therapeutic efficacy reached half of its initial
efficacy, and the shape of efficacy decay. These model parameters are illustrated in appendix figure 1.1. We then
used OpenMalaria to simulate outcomes for therapeutics with single-stage activity by deploying the pre-liver stage
or blood stage therapeutic profiles to each child alone. Outcomes for multi-stage therapeutics were simulated by
deploying the pre-liver stage and blood stage profiles to each child simultaneously. For each combination of
therapeutic profiles, we randomly sampled a range of parameter values for initial efficacy, protection half-life, and
decay shape (table 1). By simulating outcomes for this broad parameter space of protective properties, we were able
to explore the impact of combining SMC with a full spectrum of possible therapeutics. This space aims to
encompass the properties of future novel vaccines, monoclonal antibodies, and long-acting injectable drugs.

**Intervention model validation**

135 In a previous study, we validated our model's ability to accurately represent the effectiveness of SMC in
136 combination with a pre-liver stage vaccine.[27] We used OpenMalaria to replicate outcomes from the randomised
137 clinical trial of seasonal chemoprevention with or without seasonal RTS,S vaccination, conducted in Mali and
138 Burkina Faso.[7,8] Using data from the first year of the trial, OpenMalaria was able to capture outcomes for the
139 combination of SMC and RTS,S.

**Outcome measures**

Our primary outcome measures captured reductions in the cumulative incidence of uncomplicated and severe
malaria throughout childhood. We followed children born in the first year of intervention delivery and evaluated
cumulative incidence at five (as the intervention ends) and ten years old (five years after interventions have ended).
As illustrated in figure 1, we then calculated the reductions in the cumulative incidence of uncomplicated and severe
malaria attributed to the combination of SMC with SP-AQ and the novel therapeutic. Reductions were evaluated
relative to two counterfactual scenarios: regular deployment of SMC alone, and seasonal deployment of a novel
therapeutic alone (appendix section 1). We report these reductions as the percentage of burden averted by the
combination relative to a standard of care; we do not compare to a no-intervention scenario.

**Figure 1: Illustration of seasonality profiles, intervention timing, and primary outcome measures**

Panel A illustrates the two seasonal profiles modelled, where 70% of malaria cases occur within a four- or six-month period and where the y-axis represents the average annual entomological inoculation rate (EIR). Panel B illustrates interventions deployed according to four seasonal deployment scenarios. Scenario 1. Perfect deployment: All children aged between three and 59 months had perfect compliance to five yearly SMC cycles. This scenario represents an ideal clinical trial where every child is perfectly adherent to the SP-AQ chemoprevention regimen. Scenario 2. Imperfect seasonal coverage: All children aged three to 59 months had perfect compliance to four yearly SMC cycles but missed the final cycle. This scenario represents a setting where the number of SMC cycles may not provide protection for the full transmission season. Scenario 3. Imperfect deployment: All children aged three to 59 months had perfect compliance to yearly SMC cycles one, three, and five. This scenario represents a setting where children systematically miss out on multiple SMC cycles. Scenario 4. Random allocation: 30% to 100% of children were randomly selected to receive each of five yearly SMC cycles. This scenario represents a setting where children randomly miss out on one or more SMC cycles. In all four deployment scenarios, the novel prevention intervention was co-deployed seasonally together with the first cycle of SMC. Panel C illustrates the evaluation of our primary outcome measures. We tracked a cohort of children born in the first year of intervention deployment, and evaluated cumulative incidence when children were five and ten years old. We then calculated the reductions in the cumulative incidence of uncomplicated and severe malaria attributed to the combination of SMC and the novel therapeutic. Reductions were evaluated relative to two counterfactual scenarios: regular deployment of SMC alone, and seasonal deployment of a novel therapeutic alone.

## Simulation and model scenarios

The malaria transmission model was used to simulate cumulative case outcomes for a range of transmission and health system scenarios. Each model scenario captured a unique combination of the following characteristics: a low (10%) or high (50%) probability of seeking first-line treatment for clinical malaria over 14 days post-infection; 70% of malaria cases occurring within a four- or six-month transmission season (figure 1); six levels of transmission intensity ranging from low-moderate (9%) to high (64%) baseline annual prevalence. Annual prevalence was measured as the prevalence rate of *Plasmodium falciparum* infections detectable by rapid diagnostic test in children aged two to ten years old ($PfPR_{2-10}$) when no intervention was deployed. We also modelled four different seasonal deployment scenarios for SMC (perfect deployment, imperfect seasonal coverage, imperfect deployment, random allocation), as illustrated in figure 1. By varying deployment, we were able to quantify differences in the novel intervention's benefit when children are more or less covered by SMC.

## Statistical analysis

We followed an existing mathematical framework for defining essential therapeutic characteristics for malaria
prevention interventions.[28] This framework has previously been used to explore determinants of malaria intervention
impact for long-acting injectable drugs[25] and for novel seasonal malaria chemoprevention therapeutics.[29]

Following our methodology (appendix figure 1.2), we first generated a Latin hypercube sample of 500 values for the
novel intervention's parameters: therapeutic initial efficacy, protection half-life, and decay shape. For each sample,
we used our individual-based malaria transmission model to simulate outcomes with ten stochastic replicates.
Heteroskedastic Gaussian process regression models[30] were then fitted to predict primary outcome measures
(reductions in cumulative uncomplicated and severe cases at five and ten years old) as a function of intervention
inputs (initial efficacy, protection half-life, and decay shape). These models were used to emulate the relationship
between therapeutic properties and our primary outcome measures without additional simulation from the
individual-based model, which would have required intensive computation. Emulator performance was evaluated
against a 10% hold-out set. Finally, for each model scenario, we quantified the impact of a small change in each key
therapeutic property on variation in our primary outcome measures by performing a non-parametric sensitivity
analysis using the Sobol-Janssen method.[31,32] Sobol total-order indices were computed for two Latin hypercube
samples of 50 000 intervention parameters. All analyses were conducted in R.[33]

**Role of the funding source**

**Results**

**Combining SMC with seasonal deployment of a pre-liver stage therapeutic**

We first simulated cumulative case outcomes among children for exemplar malaria therapeutic profiles: one pre-
liver stage therapeutic with long duration and high efficacy (protection half-life 354 days, 90% initial efficacy) and a
second with shorter duration and partial efficacy (protection half-life 120 days, 50% initial efficacy). This allowed
us to explore the therapeutic properties needed for a pre-liver stage therapeutic to add benefit to SMC with SP-AQ.
Figure 2 depicts the cumulative incidence curves predicted by our model for two hypothetical pre-liver stage
therapeutics. First, we saw that both therapeutics contributed to reductions in cumulative uncomplicated and severe
cases by the time children were five years old (reductions >10%). This result confirmed the positive effects observed
in the randomised control trial of seasonal vaccination with RTS,S in combination with SMC,[8,9] and the R21 phase
three clinical trial.[10]

However, we saw that pre-liver stage therapeutics needed to have a long duration and high efficacy to maintain their
benefits as children aged. The exemplar 120-day duration therapeutic (figure 2) to SMC led to no observable
difference in cumulative uncomplicated cases by the time children were eight years old. Furthermore, we observed
that the combination of SMC with SP-AQ and the pre-liver stage therapeutic was more beneficial than the pre-liver
stage therapeutic alone throughout childhood. Similar patterns were observed for other SMC deployment scenarios
(appendix figures 2.1-2) and across the full range of pre-liver stage therapeutic properties (appendix figure 2.3).
Together, these findings indicate that pre-liver stage therapeutics may need a long duration to limit the potential for
delayed malaria when added to SMC and may not fully replace SMC's benefits.

**Figure 2: Predicted cumulative case curves when seasonal deployment of two exemplar pre-liver stage therapeutics are combined with SMC**

The median number of cumulative cases per year of age were calculated when children aged three to 59 months received one of the following interventions: no intervention, three SMC cycles (imperfect deployment scenario), seasonal deployment of a pre-liver stage therapeutic, or the combination of three SMC cycles and the pre-liver stage therapeutic. Top panels include deployment of a pre-liver stage therapeutic with a protection half-life of 354 days, 90% initial efficacy, and decay shape parameter of 1. Bottom panels include a pre-liver stage therapeutic with a protection half-life of 120 days, 50% initial efficacy, and decay shape parameter of 1. The pink shaded regions indicate age-eligibility for SMC and the novel therapeutic. Shaded regions indicate the minimum and maximum cumulative cases per person observed across stochastic replicates of simulations from the individual-based malaria transmission model. Model results are shown for a high transmission scenario (32% $Pf$PR$_{2-10}$) where 75% of malaria cases occur within six months of the year and the probability of seeking first-line treatment for clinical malaria over 14 days is low (10%).

In addition to a long duration, we found that pre-liver stage therapeutics needed a long tail of protection to maintain reductions in cumulative burden as children aged. Higher reductions in cumulative cases by ten years of age were observed for pre-liver stage therapeutics with a long tail of protection, encompassing exponential and biphasic decay profiles (decay shape <1, figure 3A), in comparison to sigmoidal decay (decay shape >1). For example, in figure 3A, deploying a pre-liver stage therapeutic with a decay shape parameter between 0·6 and 0·8 was associated with a 9·9% median reduction (interquartile range 5·5-16·0% across the parameter range for protection half-life and initial efficacy) in cumulative uncomplicated cases by the time children were ten years old, evaluated relative to SMC alone. In contrast, deploying a therapeutic with a decay shape between 4·0 and 4·2 led to a lower median reduction of 5·3% (interquartile range 1·8-10·0%). Similar findings were observed across deployment scenarios (appendix figures 2.4-2.6).

## A. Parameter relationships with cumulative case outcomes

Uncomplicated cases   —  — Severe cases

## B. Parameter relationships with SMC deployment

**Figure 3: Gaussian Process regression emulator predictions for the relationship between pre-liver stage therapeutic properties and reductions in cumulative uncomplicated and severe cases relative to SMC alone**

Panel A shows the imperfect deployment scenario, where children aged three to 59 months received three SMC cycles. Transmission is high (32% $Pf$PR$_{2-10}$), 75% of malaria cases occur within six months of the year, and the probability of seeking first-line treatment for clinical malaria over 14 days is low (10%). Each panel shows the median reduction in cumulative uncomplicated (solid lines) or severe cases (dashed lines) achieved by combining seasonal deployment of a pre-liver stage therapeutic with SMC, relative to cumulative cases when SMC is deployed alone. Median reductions are calculated by dividing the parameter range for the therapeutic property shown on the x-axis (protection half-life, initial efficacy, decay shape) into 51 segments, and calculating the median outcome for each given segment across all other parameter values. Shaded regions represent the 25% and 75% quantiles of the corresponding reductions. Predictions are shown separately for cumulative case outcomes at five (top panels) and ten years old (bottom panels). Panel B shows the predicted relationships between pre-liver stage protection half-life, initial efficacy and reductions in cumulative severe cases by ten years old, compared across SMC deployment scenarios. Grid squares indicate the predicted reduction if a pre-liver stage therapeutic with the given protection half-life (x-axis) and initial efficacy (y-axis) were deployed in addition to SMC, assuming a long tail of protection (decay shape parameter 0·7). Reductions are rounded to the nearest 5%. Results

show a scenario where transmission is high (32% $Pf$PR$_{2-10}$), 75% of malaria cases occur within six months of the year, and the probability of
seeking first-line treatment for clinical malaria over 14 days is low (10%). Panels depict predicted relationships for four different SMC
deployment scenarios. In deployment scenario 4, SMC coverage is fixed at 70%.

Our results showed that co-deploying SMC with a pre-liver stage therapeutic is likely to have the most impact in
settings where SMC does not fully protect children. For example, for a pre-liver stage therapeutic with 50% initial
efficacy and a long tail of protection (biphasic decay shape 0·7) deployed with three yearly cycles of SMC, a target
5% reduction in cumulative severe cases by ten years old required a protection half-life of at least 237 days (figure
3B). For the same therapeutic profile, a protection half-life of at least 237 days corresponded to a reduction in severe
cases by five years old of more than 23%. When the same therapeutic was combined with five SMC cycles,
however, a 5% reduction required a protection half-life of at least 340 days. Results also indicated that higher initial
efficacy could be traded for shorter duration requirements; in figure 3B, the target 5% reduction in cumulative
severe cases by ten years old could be achieved with a protection half-life of 153 days if pre-liver stage initial
efficacy were 70%. Similar results were observed across seasonal transmission settings and levels of access to care.
(appendix figures 2.7-8)

**Combining SMC with seasonal deployment of a blood stage therapeutic**

Our results indicate that combining a blood stage therapeutic with SMC is likely to reduce the occurrence of severe
malaria but may not reduce uncomplicated cases. When a blood stage therapeutic was combined with SMC,
increasing a therapeutic's initial efficacy or protection half-life led to limited change in reductions in uncomplicated
malaria. As shown in figure 4, a near-perfect initial blood stage efficacy of 95·8% was required to achieve a positive
median reduction in cumulative uncomplicated cases by ten years old. In contrast, a 10% reduction in cumulative
severe cases could be achieved with an initial blood stage efficacy of 86%. Similar trends were observed across
SMC deployment scenarios (appendix figures 3.1-3.3).

**A. Blood stage parameter relationships with cumulative case outcomes by five years old**

**B. Blood stage parameter relationships with cumulative case outcomes by ten years old**

—— Uncomplicated cases   – – Severe cases

**Figure 4: Gaussian Process regression emulator predictions for the relationship between blood stage therapeutic properties and expected reductions in cumulative uncomplicated and severe cases relative to SMC alone**

Results show the imperfect deployment scenario, where children aged three to 59 months received three SMC cycles. Transmission is high (32% $Pf$PR$_{2-10}$), 75% of malaria cases occur within six months of the year, and the probability of seeking first-line treatment for clinical malaria over 14 days is low (10%). Each panel shows the median reduction in cumulative uncomplicated (solid lines) or severe cases (dashed lines) achieved by combining seasonal deployment of a blood stage therapeutic with SMC, relative to cumulative cases when SMC is deployed alone. Median reductions are calculated by dividing the parameter range for the therapeutic property shown on the x-axis (protection half-life, initial efficacy, decay shape) into 51 segments, and calculating the median outcome for each given segment across all other parameter values. Shaded regions represent the 25% and 75% quantiles of the corresponding reductions. Emulator predictions are shown separately for cumulative case outcomes at five (panels A) and ten years old (panels B).

**Combining SMC with seasonal deployment of a multi-stage therapeutic**

Finally, results suggest that multi-stage therapeutics with both pre-liver and blood stage activity may be preferred for interventions that aim to reduce the burden of severe malaria in children. When three SMC cycles were deployed with a multi-stage therapeutic with both pre-liver and blood stage activity, we found that pre-liver stage activity was the primary driver of impact on cumulative uncomplicated cases. More than 70% of variation in uncomplicated case outcomes was attributed to the combined impact of the pre-liver stage component's initial efficacy and protection half-life (figure 5, panel A). However, blood stage activity was crucial for impact on cumulative severe cases, particularly by the time children were ten years old; up to 89% of variation in the reduction in cumulative severe

293    cases could be attributed to the blood stage component's initial efficacy and protection half-life (figure 5, panel A).

294    Similar trends occurred across levels of access to care and transmission seasonality (appendix figure 4.1).

**Figure 5: Impact of combining a therapeutic with both pre-liver stage and blood stage activity with three yearly cycles of SMC on cumulative uncomplicated and severe cases, compared with SMC deployed alone**

Panel A shows the drivers of impact on all cumulative case outcomes for a therapeutic with both pre-liver stage and blood stage activity deployed
together with three yearly cycles of SMC, compared with SMC deployed alone. Bars show the total Sobol effect indices for intervention model
parameters. Total Sobol effect indices can be interpreted as the proportion of variation in the cumulative case outcome that can be attributed to a
small change in each model parameter and its interactions with other parameters. Indices are shown across levels of transmission intensity (x-
axis) for a scenario where three yearly cycles of SMC are deployed (imperfect coverage scenario) in a setting where 75% of malaria cases occur
within six months of the year and the probability of seeking first-line treatment for clinical malaria over 14 days is low (10%). Panel B shows
differences in the median impact on cumulative case outcomes for therapeutics with pre-liver stage activity alone, blood stage activity alone, and

multi-stage pre-liver stage and blood stage activity. Results are shown for the same scenario as in panel A. Points in each panel show the median expected reduction in cumulative cases achieved by combining seasonal deployment of a pre-liver stage, blood stage, or multi-stage therapeutic with SMC, relative to cumulative cases when SMC is deployed alone. Median reductions are evaluated across all possible combinations of therapeutic initial efficacy, protection half-life, and decay shape. Bars indicate the 25% and 75% quantiles of the corresponding reductions.

Importantly, model results indicated that deploying a therapeutic with combined pre-liver stage and blood stage activity could lead to greater impact than either therapeutic component alone. When children received three SMC cycles, the expected gain in median outcome between therapeutics with pre-liver stage activity alone and both pre-liver stage and blood stage activity was up to 22·5% across levels of transmission intensity for reductions by five years old, and up to 9·4% for reductions by ten years old (figure 5, panel B). This trend occurred across SMC deployment scenarios (appendix figures 4.2-4.4). This result suggests that multi-stage therapeutics layered with SMC may offer substantial additional benefit for malaria outcomes in comparison to a single-stage therapeutic.

**Discussion**

We used mathematical modelling to estimate the potential benefits of deploying SMC to children under five years in combination with a range of novel prevention therapeutics with both single- and multi-stage targets. We compared the benefits of the combined interventions to either SMC with SP-AQ or to the new therapeutic alone, capturing cumulative patterns in malaria uncomplicated and severe cases by five years of age, during intervention deployment, and at ten years of age, five years after deployment had stopped. To identify the therapeutic profiles that would result in added benefit from combining with SMC over SMC deployed alone, our results showed that developers of pre-liver stage therapeutics will need to prioritise candidates with a long duration (>230 days) and long tail of protection (exponential or biphasic decay). Conversely, we found that combining SMC with a new therapeutic always had added benefit compared with the therapeutic deployed alone. We also demonstrated the benefit of a therapeutic with both pre-liver stage and blood stage activity for impact on severe disease outcomes, highlighting the need for developers to prioritise multi-stage malaria therapeutics in particular.

Our results support continued investment in research and development for pre-liver stage malaria therapeutics that meet minimum duration and efficacy criteria. In particular, we found that when a pre-liver stage therapeutic was combined with three cycles of SMC in a high transmission setting, a protection half-life of more than 230 days, an initial efficacy of more than 50%, and a long tail of protection were required to maintain reductions in severe cases by ten years of age. This suggests a likely role for improved malaria vaccines in combination with SMC, rather than a pre-liver stage therapeutic with rapid decay. This work did not specifically attempt to model outcomes for either of the two approved malaria vaccines, RTS,S and R21 and we did not incorporate waning boosting efficacy into our therapeutic models. However, if the goal of deploying SMC in combination with a novel therapeutic is to sustain reductions in severe malaria throughout childhood, our results suggest that these therapeutics will require either extended pre-liver stage duration or multi-stage activity.

This modelling study is the first to articulate the potential benefits of a malaria prevention active against multiple stages of the parasite life cycle. Importantly, our work highlights a public health need for a malaria therapeutic with both pre-liver stage and blood stage activity. Model results indicated that combining a multi-stage therapeutic with SMC led to greater reductions in cumulative severe cases throughout childhood than therapeutics with single stage activity. And, while we did not look at all-infection outcomes, we anticipate that multi-stage activity will be needed to support reductions in malaria prevalence. Currently, the only approved malaria therapeutics with both liver and blood stage activity are oral antimalarial drugs such as SP-AQ. In the near future, this gap could be filled with the development of long-acting injectable formulation of an antimalarial drug that is active against multiple stages of the parasite life cycle.[14–17] In the longer term, we could expect substantial benefit from layering SMC with a combination vaccine such as RTS,S or R21 combined with an RH5-based vaccine candidate (ClinicalTrials.gov ID NCT05357560),[19] or monoclonal antibody.

Our results also suggest that combining a novel malaria therapeutic with SMC is likely to lead to the greatest public
health benefits in settings where there are gaps in SMC's effectiveness. A new vaccine, monoclonal antibody, or
long-acting injectable can provide an additional layer of protection for children with poor adherence to SP-AQ, who
are absent for one or more SMC cycles, or who reside in regions where SP's efficacy has been compromised by
parasite resistance. A new therapeutic can also supplement SMC's protection for the period between cycles when
SP-AQ's protection has waned or when the number of SMC cycles does not fully cover the malaria transmission
season.[34]

On the other hand, our results indicate that SMC may not need the support of a new therapeutic when coverage is
already high. A longer pre-liver stage protection half-life was needed for a novel therapeutic to contribute additional
reductions in malaria burden when children received five cycles of SMC. This result is consistent with previous
modelling studies; modelling has indicated that synergisms between a pre-liver stage vaccine and mass drug
administration are lost when coverage was high,[35] and we have previously demonstrated that increasing SMC's
coverage through, for example, the deployment of a new oral chemoprevention drug can lead to substantial increases
in SMC's effectiveness.[29]

These trade-offs between SMC's coverage and the benefits of a partner therapeutic imply that the cost-effectiveness
of a new therapeutic will depend on the public health effectiveness of existing interventions. The number of children
missed by SMC varies across programs. For example, the ACCESS-SMC project found that SMC coverage varied
between countries; as few as 24% of children in Chad and as many as 86% of children in Burkina Faso received all
four cycles of SP-AQ.[5] We did not model cost-effectiveness outcomes in this work, due to the uncertainties inherent
in costs for therapeutics that are still being developed. However, our results indicate that adding seasonal
deployment of a pre-liver stage vaccine to SMC may not be cost-effective when SMC's coverage has been
optimised and the efficacy of SP-AQ remains high. Our results also highlight the important conceptual difference
between evaluating an intervention with respect to its absolute number of malaria cases averted and relative to the
standard of care; any assessment of intervention cost-effectiveness should be coupled with a strong understanding of
the absolute malaria burden in a setting.

All modelling studies are limited by their assumptions. In this study, we measured impact on the cumulative
incidence of uncomplicated and severe cases throughout childhood. These outcomes do not capture the potential
benefits of malaria chemoprevention for non-malarial health outcomes, and depend strongly on our transmission
model's assumptions about the relationships between infection density, malaria immunity acquisition, and the
development of clinical disease.[23,24] Future studies of intervention combinations with data from clinical trials and
with alternative health outcomes will be important to confirm the findings of our work, and validate or support
changes to model assumptions on anti-parasite and anti-disease immunity.

In addition, we made assumptions within our model structure to represent the dynamics of our malaria preventive
therapeutics. The model structures used have been previously validated to data for pre-liver stage vaccines and blood
stage antimalarial drugs, having been used to estimate the expected public health impact or RTS,S[36] and SMC.[25,29]
However, to date, no blood stage vaccines, monoclonal antibodies, or long-acting injectable drugs have been
approved by the World Health Organization for use in malaria prevention. Hence, there is limited data available to
validate a model structure for the effects of a blood stage therapeutic; new modelling evidence will be needed as
blood stage and multi-stage therapeutics advance through clinical trials.

Finally, our estimates of benefit were based on outcomes simulated from a limited number of deployment modalities
and endemic settings. In particular, we focused on evaluating the impact of combining a novel therapeutic with SMC
in high transmission settings, where new tools are most needed to reduce the burden of malaria. Future modelling
studies could explore combinations in perennial settings and for other use-cases and target age-groups. We also did
not investigate how sex, gender, or ethnicity would influence our study outcomes, due to the limited data available
for validating estimates of intervention effectiveness across these different groups. As a result of these limitations,

our work does not offer forecasts of likely therapeutic impact when combined with a chemoprevention program. We instead aim to provide evidence to support investment decisions and inform candidate selection.

**Conclusion**

In conclusion, this study has provided quantitative evidence to articulate the benefits of new malaria prevention therapeutics during childhood. Our evidence provides funders and policymakers with new understandings of how interventions can be combined to provide added benefits over the standard of care before clinical trials. Results demonstrate the importance of prioritising co-deployment of a novel therapeutic in settings with limited coverage or effectiveness of SMC and deprioritising when the effectiveness of SMC has already been optimised. For the first time, our results demonstrate the potential for a multi-stage malaria therapeutic to improve a program's ability to maintain benefits for children in the years after the deployment of an intervention has stopped.

**Contributors**

MAP and LBM designed the study. LBM developed and performed analyses. LBM, JM, NN, SLK, and MAP validated the model, analyses, and results. JJM provided expertise and input on therapeutic development for malaria prevention candidates. LBM prepared figures and drafted the manuscript. All authors contributed to interpreting the results and making edits to the draft and final manuscript and gave their final approval for publication.

**Declaration of interests**

JJM was an employee of Medicines Malaria Venture.

**Data sharing**

All code and datasets are available on GitHub https://github.com/lydiab-mayer/modelling-malaria-combination-interventions/releases/tag/v1.0.0).

**Acknowledgements**

LBM, JM, NN, and SLK were funded by the Bill & Melinda Gates Foundation (INV-002562 to MAP). MAP acknowledges support from the Swiss National Science Foundation (SNF Professorship PP00P3_170702 and PP00P3_203450). JJM was an employee of Medicines for Malaria Venture (MMV). We wish to thank Dr Jean-Luc Bodmer (Bill & Melinda Gates Foundation) for his contribution to this project. We would also like to thank Dr Thiery Masserey for his project management support and acknowledge support and advice from all members of the Disease Modelling research unit of the Swiss Tropical and Public Health Institute. Calculations were performed at sciCORE (http://scicore.unibas.ch/) scientific computing centre at the University of Basel.

**References**

Walker SP, Wachs TD, Meeks Gardner J, *et al.* Child development: risk factors for adverse outcomes in developing countries. *The Lancet* 2007; **369**: 145–57.

World Health Organization. World Malaria Report 2023. Geneva: World Health Organization, 2024 https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2023 (accessed June 5, 2024).

Fink G, Mrema S, Abdulla S, *et al.* Mosquito Net Use in Early Childhood and Survival to Adulthood in Tanzania. *N Engl J Med* 2022; **386**: 428–36.

World Health Organization. WHO Guidelines for Malaria - 16 October 2023. Geneva: World Health Organization, 2023 https://app.magicapp.org/#/guideline/7663 (accessed June 5, 2024).

ACCESS-SMC Partnership. Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. *Lancet* 2020; **396**: 1829–40.

Plowe CV. Malaria chemoprevention and drug resistance: a review of the literature and policy implications. *Malar J* 2022; **21**: 104.

Chandramohan D, Zongo I, Sagara I, *et al.* Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention. *N Engl J Med* 2021; **385**: 1005–17.

Dicko A, Ouedraogo JB, Zongo I, *et al.* Seasonal vaccination with RTS,S/AS01(E) vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial. *Lancet Infect Dis* 2024; **24**: 75–86.

Cairns M, Barry A, Zongo I, *et al.* The duration of protection against clinical malaria provided by the combination of seasonal RTS,S/AS01(E) vaccination and seasonal malaria chemoprevention versus either intervention given alone. *BMC Med* 2022; **20**: 352.

Datoo MS, Dicko A, Tinto H, *et al.* Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. *The Lancet* 2024; **403**: 533–44.

Thompson HA, Hogan AB, Walker PGT, *et al.* Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study. *Lancet Glob Health* 2022; **10**: e1782–92.

Kayentao Kassoum, Ongoiba Aissata, Preston Anne C., *et al.* Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria. *N Engl J Med* 2024; **390**: 1549–59.

Nekkab N, Penny MA. Accelerated development of malaria monoclonal antibodies. *Cell Rep Med* 2022; **3**: 100786.

Moehrle JJ. Development of New Strategies for Malaria Chemoprophylaxis: From Monoclonal Antibodies to Long-Acting Injectable Drugs. *Trop Med Infect Dis* 2022; **7**: 58.

Burrows JN, Duparc S, Gutteridge WE, *et al.* New developments in anti-malarial target candidate and product profiles. *Malar J* 2017; **16**: 26.

Medicines for Malaria Venture. MMV Annual Report 2022. Medicines for Malaria Venture, 2023 https://www.mmv.org/newsroom/news-resources-search/mmv-annual-report-2022 (accessed July 10, 2024).

Bakshi RP, Tatham LM, Savage AC, *et al.* Long-acting injectable atovaquone nanomedicines for malaria prophylaxis. *Nat Commun* 2018; **9**: 315.

Sirima SB, Ouédraogo A, Tiono AB, *et al.* A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria. *Sci Transl Med* 2022; **14**: eabj3776.

Williams BG, King LDW, Pulido D, *et al.* Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex. *Nat Commun* 2024; **15**: 4857.

Duffy PE, Patrick Gorres J. Malaria vaccines since 2000: progress, priorities, products. *Npj Vaccines* 2020; **5**: 1–9.

Reiker T, Golumbeanu M, Shattock A, *et al.* Emulator-based Bayesian optimization for efficient multi-objective calibration of an individual-based model of malaria. *Nat Commun* 2021; **12**: 7212.

Collins WE, Jeffery GM. A retrospective examination of the patterns of recrudescence in patients infected with Plasmodium falciparum. *Am J Trop Med Hyg* 1999; **61**: 44–8.

23 Maire N, Smith TA, Ross A, Owusu-Agyei S, Dietz K, Molineaux L. A model for natural immunity to asexual
blood stages of Plasmodium falciparum malaria in endemic areas. *Am J Trop Med Hyg* 2006; **75**: 19–31.

24 Smith TA, Ross A, Maire N, Rogier C, Trape JF, Molineaux L. An epidemiologic model of the incidence of
acute illness in Plasmodium falciparum malaria. *Am J Trop Med Hyg* 2006; **75**: 56–62.

25 Burgert L, Reiker T, Golumbeanu M, Moehrle JJ, Penny MA. Model-informed target product profiles of long-
acting-injectables for use as seasonal malaria prevention. *PLOS Glob* 2022; **2**: e0000211.

26 Zongo I, Milligan P, Compaore YD, *et al.* Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine
Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in
Burkina Faso. *Antimicrob Agents Chemother* 2015; **59**: 4387–96.

27 Malinga J, Braunack-Mayer L, Masserey T, *et al.* Performance characteristics and potential public health impact
of improved pre-erythrocytic malaria vaccines targeting childhood burden. 2024; published online Nov 12.
DOI:10.1101/2024.11.12.24317082.

28 Golumbeanu M, Yang GJ, Camponovo F, *et al.* Leveraging mathematical models of disease dynamics and
machine learning to improve development of novel malaria interventions. *Infect Poverty* 2022; **11**.
DOI:10.1186/s40249-022-00981-1.

29 Braunack-Mayer L, Malinga J, Masserey T, *et al.* Design and selection of drug properties to increase the public
health impact of next-generation seasonal malaria chemoprevention: a modelling study. *Lancet Glob Health*
2024; **12**: e478–90.

30 Binois M, Gramacy RB. hetGP: Heteroskedastic Gaussian Process Modeling and Sequential Design in R. *J Stat*
*Softw* 2021; **98**: 1–44.

31 Sobol IM. Global sensitivity indices for nonlinear mathematical models and their Monte Carlo estimates. *Math*
*Comput Sim* 2001; **55**: 271–80.

32 Iooss B, Da Veiga S, Janon A, Pujol G. Global sensitivity analysis of model outputs. 2021.

33 R Core Team. R: A language and environment for statistical computing. 2021. https://www.R-project.org/.

34 Greenwood B, Cairns M, Chaponda M, *et al.* Combining malaria vaccination with chemoprevention: a promising
new approach to malaria control. *Malar J* 2021; **20**: 361.

35 Camponovo F, Ockenhouse CF, Lee C, Penny MA. Mass campaigns combining antimalarial drugs and anti-
infective vaccines as seasonal interventions for malaria control, elimination and prevention of resurgence: a
modelling study. *BMC Infect Dis* 2019; **19**: 920.

36 Penny MA, Verity R, Bever CA, *et al.* Public health impact and cost-effectiveness of the RTS,S/AS01 malaria
vaccine: a systematic comparison of predictions from four mathematical models. *Lancet* 2016; **387**: 367–75.

502